MedTrace Pharma’s Novel 15O-Water Technology Showcased at the SNMMI 2023 Annual Meeting

MedTrace Pharma is proud to participate with a clinical booth and share the latest about its ongoing Phase 3 Clinical Trial RAPID-WATER-FLOW at this year’s Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2023 annual conference.

The company announced recently that the first U.S. study subject was dosed using its 15O-water point-of-care system (P3 MT-100) as part of the Phase 3 Clinical Trial. In addition, MedTrace has a software solution in development (aQuant) that provides quantitative and visual 15O-water image analysis, including quantification of blood flow and segmental perfusion data.

  • The SNMMI 2023 Annual Meeting takes place  June 24-27, 2023, in Chicago, IL.

  • MedTrace Pharma will be showcasing demonstrations of its novel technology, currently under development and available for investigational research, at clinical booth #4000. 
    • Automated 15O-water manufacturing system (P3 MT-100) produces, doses and injects 15O-water in patients prior to PET scans. The company is working on regulatory approval in the U.S. and Europe.   
    • aQuant software is being developed to provide a fully automated analysis of quantitative MBF and cardiac function using 15O-water, with user input only required for confirmation and quality control

  • The MedTrace Clinical Affairs Team will be available to discuss its Phase 3 Clinical Trial that seeks to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion PET imaging agent and share the latest on 15O-water research findings from around the globe.

Reach out in advance to book a demonstration or meeting with the Clinical Affairs, Market Development, or Executive Team.

Contact for Clinical:

Emily Vandenbroucke
Director, Clinical Affairs
emily@medtracepharma.com
+1 312 805 0489

Contact for Non-Clinical:

Mitzi Cloud
VP, Head of Market Development 
mitzi@medtracepharma.com 
+1 (813) 503-8090